Finally, Lifesci Capital assumed coverage on Arcus Biosciences in a research note on Thursday, June 4th. Get Arcus Biosciences alerts:Read Our Latest Report on Arcus BiosciencesArcus Biosciences Stock Down 0.4%Arcus Biosciences stock traded down $0.12 during midday trading on Thursday, hitting $27.59. Insider Transactions at Arcus BiosciencesIn other news, CAO Alexander Azoy sold 2,562 shares of Arcus Biosciences stock in a transaction that occurred on Monday, June 1st. Arcus Biosciences Company Profile(Get Free Report)Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. Read MoreReceive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.